Winkelmann, Michael http://orcid.org/0000-0003-4655-7341
Blumenberg, Viktoria
Rejeski, Kai
Bücklein, Veit L.
Ingenerf, Maria
Unterrainer, Marcus
Schmidt, Christian
Dekorsy, Franziska J.
Bartenstein, Peter
Ricke, Jens
von Bergwelt-Baildon, Michael
Subklewe, Marion
Kunz, Wolfgang G. http://orcid.org/0000-0002-5021-1952
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 10 January 2023
Accepted: 6 May 2023
First Online: 15 May 2023
Declarations
:
: All medical records and imaging studies were reviewed with the approval of the LMU Munich Institutional Review Board (LMU Ethics Committee, project number 19–817). Informed consent was obtained from all individual participants included in the study.
: <b>V.B.</b>: BMS/Celgene: Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding; Janssen: Research Funding, Honoraria; Novartis: Research Funding, Honoraria,; Roche: Research Funding; Takeda: Research Funding. <b>K.R.</b>: Kite/Gilead: Research Funding; Kite/Gilead: Travel Support; Novartis: Honoraria. <b>V.L.B.</b>: Amgen: Honoraria; Celgene/BMS: Research Funding; Kite/Gilead: Research Funding, Honoraria; Novartis: Honoraria; Pfizer: Honoraria. <b>C.S.</b>: Kite/Gilead: Travel Support. <b>M.v.B.</b>: Astellas: Consultancy, Research Funding and Honoraria; BMS: Consultancy, Research Funding and Honoraria; Kite/Gilead: Consultancy, Research Funding and Honoraria; Miltenyi: Consultancy, Research Funding and Honoraria; Mologen: Consultancy, Research Funding and Honoraria; MSD Sharp & Dohme: Consultancy, Research Funding and Honoraria; Novartis: Consultancy, Research Funding and Honoraria; Roche: Consultancy, Research Funding and Honoraria. <b>M.S.</b>: Amgen: Research Funding, Speakers Bureau; Astra Zeneca: Speakers Bureau; Aven Cell: Consultancy, BMS/Celgene: Research Funding, Speakers Bureau; CDR-Life: Consultancy, Gilead: Research Funding, Speakers Bureau; GSK: Speakers Bureau; Ichnos Sciences: Consultancy; Incyte Biosciences: Consultancy; Janssen: Research Funding, Consultancy, Speakers Bureau; Miltenyi Biotec: Research Funding, Consultancy; Morphosys: Research Funding; Molecular Partners: Consultancy; Novartis: Research Funding, Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Roche: Research Funding, Speakers Bureau; Seattle Genetics: Research Funding; Takeda: Research Funding, Consultancy, Speakers Bureau. <b>W.G.K.</b>: Bristol Myers Squibb: Advisor. The remaining authors declare no competing financial interests. None of the mentioned conflicts of interest were related to financing of the content of this manuscript.